Rhafaela Causin

Mrs. Rhafaela Causin

Barretos Cancer Hospital
orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
AFAna Julia Aguiar de Freitas
Ana Julia Aguiar de Freitas
RCRhafaela Causin
Rhafaela Causin
Muriele Bertagna VaruzzaMuriele Bertagna Varuzza
Muriele Bertagna Varuzza
SCStéphanie Calfa
Stéphanie Calfa
CFCassio Murilo Trovo Hidalgo Filho
Cassio Murilo Trovo Hidalgo Filho
MMMarcia Marques
Marcia Marques
Breast cancer (BC) is a highly heterogeneous disease. The treatment of BC is complicated owing to intratumoral complexity. Tissue biopsy and immunohistochemistry are the current gold standard techniques to guide breast cancer therapy; however, these techniques do not assess tumoral molecular heterogeneity. Personalized medicine aims to overcome these biological and clinical complexities. Advances in techniques and computational analyses have enabled increasingly sensitive, specific, and accurate application of liquid biopsy. Such progress has ushered in a new era in precision medicine, where the objective is personalized treatment of breast cancer, early screening, accurate diagnosis and prognosis, relapse detection, longitudinal monitoring, and drug selection. Liquid biopsy can be defined as the sampling of components of tumor cells that are released from a tumor and/or metastatic deposits into the blood, urine, feces, saliva, and other biological substances. Such components include circulating tumor cells (CTCs), circulating tumor DNA (ctDNA) or circulating tumor RNA (ctRNA), platelets, and exosomes. This review aims to highlight the role of liquid biopsy in breast cancer and precision medicine.

1 September 2018 in Gynecologic Oncology
Verified
Journal Article
Closed access
CRCaroline Domingues Rogeri
Caroline Domingues Rogeri
Henrique SilveiraHenrique Silveira
Henrique Silveira
RCRhafaela Causin
Rhafaela Causin
LVLuisa Lina Villa
Luisa Lina Villa
MSMaíra Degiovani Stein
Maíra Degiovani Stein
JFJosé Humberto T.G. Tavares Guerreiro Fregnani
José Humberto T.G. Tavares Guerreiro Fregnani

17 March 2021 in Cells
Verified
Journal Article
Open access
PDF file
RCRhafaela Causin
Rhafaela Causin
AFAna Julia Aguiar de Freitas
Ana Julia Aguiar de Freitas
CFCassio Murilo Trovo Hidalgo Filho
Cassio Murilo Trovo Hidalgo Filho
RRRicardo Dos Reis
Ricardo Dos Reis
RRRui M. Reis
Rui M. Reis
MMMarcia Marques
Marcia Marques
To obtain a better understanding on the role of microRNAs in the progression of cervical cancer, a systematic review was performed to analyze cervical cancer microRNA studies. We provide an overview of the studies investigating microRNA expression in relation to cervical cancer (CC) progression, highlighting their common outcomes and target gene interactions according to the regulatory pathways. To achieve this, we systematically searched through PubMed MEDLINE, EMBASE, and Google Scholar for all articles between April 2010 and April 2020, in accordance with the PICO acronym (participants, interventions, comparisons, outcomes). From 27 published reports, totaling 1721 cases and 1361 noncancerous control tissue samples, 26 differentially expressed microRNAs (DEmiRNAs) were identified in different International Federation of Gynecology and Obstetrics (FIGO) stages of cervical cancer development. It was identified that some of the dysregulated microRNAs were associated with specific stages of cervical cancer development. The results indicated that DEmiRNAs in different stages of cervical cancer were functionally involved in several key hallmarks of cancer, such as evading growth suppressors, enabling replicative immortality, activation of invasion and metastasis, resisting cell death, and sustained proliferative signaling. These dysregulated microRNAs could play an important role in cervical cancer’s development. Some of the stage-specific microRNAs can also be used as biomarkers for cancer classification and monitoring the progression of cervical cancer.

8 August 2019 in Journal of Oncology
Verified
Journal Article
Open access
PDF file
KSKaren C. B. Souza
Karen C. B. Souza
AEAdriane Evangelista
Adriane Evangelista
LLLetícia F. Leal
Letícia F. Leal
CSCristiano Souza
Cristiano Souza
RVRené A. Vieira
René A. Vieira
MMMarcia Marques
Marcia Marques
Early detection is crucial for achieving a reduction in breast cancer mortality. Analysis of circulating cell-free microRNAs present in the serum of cancer patients has emerged as a promising new noninvasive biomarker for early detection of tumors and for predicting their molecular classifications. The rationale for this study was to identify subtype-specific molecular profiles of cell-free microRNAs for early detection of breast cancer in serum. Fifty-four early-stage breast cancers with 27 age-matched controls were selected for circulating microRNAs evaluation in the serum. The 54 cases were molecularly classified (luminal A, luminal B, luminal B Her2 positive, Her-2, triple negative). NanoString platform was used for digital detection and quantitation of 800 tagged microRNA probes and comparing the overall differences in serum microRNA expression from breast cancer cases with controls. We identified the 42 most significant (P ≤ 0.05, 1.5-fold) differentially expressed circulating microRNAs in each molecular subtype for further study. Of these microRNAs, 19 were significantly differentially expressed in patients presenting with luminal A, eight in the luminal B, ten in luminal B HER 2 positive, and four in the HER2 enriched subtype. AUC is high with suitable sensitivity and specificity. For the triple negative subtype miR-25-3p had the best accuracy. Predictive analysis of the mRNA targets suggests they encode proteins involved in molecular pathways such as cell adhesion, migration, and proliferation. This study identified subtype-specific molecular profiles of cell-free microRNAs suitable for early detection of breast cancer selected by comparison to the microRNA profile in serum for female controls without apparent risk of breast cancer. This molecular profile should be validated using larger cohort studies to confirm the potential of these miRNA for future use as early detection biomarkers that could avoid unnecessary biopsy in patients with a suspicion of breast cancer.

31 October 2021 in Cancers
Verified
Journal Article
Open access
PDF file
AFAna Julia Aguiar de Freitas
Ana Julia Aguiar de Freitas
RCRhafaela Causin
Rhafaela Causin
Muriele Bertagna VaruzzaMuriele Bertagna Varuzza
Muriele Bertagna Varuzza
CFCassio Murilo Trovo Hidalgo Filho
Cassio Murilo Trovo Hidalgo Filho
VSVinicius Duval da Silva
Vinicius Duval da Silva
MMMarcia Marques
Marcia Marques
Neoadjuvant chemotherapy (NAC) is often used to treat locally advanced disease for tumor downstaging, thus improving the chances of breast-conserving surgery. From the NAC response, it is possible to obtain prognostic information as patients may reach a pathological complete response (pCR). Those who do might have significant advantages in terms of survival rates. Breast cancer (BC) is a heterogeneous disease that requires personalized treatment strategies. The development of targeted therapies depends on identifying biomarkers that can be used to assess treatment efficacy as well as the discovery of new and more accurate therapeutic agents. With the development of new “OMICS” technologies, i.e., genomics, transcriptomics, and proteomics, among others, the discovery of new biomarkers is increasingly being used in the context of clinical practice, bringing us closer to personalized management of BC treatment. The aim of this review is to compile the main biomarkers that predict pCR in BC after NAC.

6 September 2019 in Oncology Letters
Verified
Journal Article
Open access
PDF file
RCRhafaela Causin
Rhafaela Causin
KSKaren Cristina Borba Souza
Karen Cristina Borba Souza
AEAdriane Feijó Evangelista
Adriane Feijó Evangelista
RRRui M. Reis
Rui M. Reis
DPDanielle Pessôa‑Pereira
Danielle Pessôa‑Pereira
MMMarcia Marques
Marcia Marques
Screening for cervical cancer by cytology has been effective in reducing the worldwide incidence and mortality rates of this disease. However, a number of studies have demonstrated that the sensitivity of conventional cervical cytology may be too low for detection of cervical intraepithelial neoplasias (CIN). Therefore, it is important to incorporate more sensitive molecular diagnostic tests that could substantially improve the detection rates and accuracy for identifying CIN lesions. MicroRNAs (miRNAs) are a class of small non‑coding RNAs with the potential to provide robust non‑invasive cancer biomarkers for detecting CIN lesions in liquid‑based cervical cytology (LBC) samples. At present, there is no consensus on which are the best housekeeping genes for miRNA normalization in LBC. The present study aimed to identify housekeeping genes with consistent and reproducible performance for normalization of reverse transcription‑quantitative PCR (RT‑qPCR) expression analysis of miRNA using LBC samples. The present study firstly selected six potential candidate housekeeping genes based on a systematic literature evaluation. Subsequently, the expression levels of microRNAs U6, RNU‑44, RNU‑47, RNU‑48, RNU‑49 and hsa‑miR‑16 were measured in 40 LBC samples using RT‑qPCR. The stability of each potential housekeeping gene was assessed using the NormFinder algorithm. The results revealed that U6 and RNU‑49 were the most stable genes among all candidates requiring fewer amplification cycles and smaller variation across the sample set. However, RNU‑44, RNU‑47, RNU‑48 and hsa‑miR‑16 stability exceeded the recommended housekeeping value suitable for normalization. The findings revealed that U6 may be a reliable housekeeping gene for normalization of miRNA RT‑qPCR expression analysis using LBC samples.